)
)
)
Sebastian BioPharma is a preclinical oncology company developing tumor-targeted, multi-pathway therapeutics for colorectal cancer and other immunotherapy-resistant solid tumors. Our lead program uses a dual payload antibody–oligonucleotide conjugate approach designed to overcome tumor immune escape while reducing systemic toxicity, with expansion potential across additional solid tumors.
Year Founded
2025
Next catalyst (value inflection) update
Lead candidate nomination
Expected time of next catalyst update
Q4 2026 lead candidate nomination for SBP-001, establishing a clear inflection point ahead of IND-enabling studies.
City
Beverly
Country
United States
Company CEO or top company official
Greta Garrido
Development Phase of Primary Product
Discovery
Lead Product in Development
SBP-001, a tumor-targeted dual payload antibody–oligonucleotide conjugate designed to overcome immune resistance in colorectal cancer
Number of Unlicensed Products
1
Therapeutic Area
Oncology
Website
https://sebastianbio.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
